AptarGroup and Sonmol have announced a collaboration for developing a digital therapies and services platform targeting respiratory and other diseases.
This collaboration will initially focus on bringing together connected drug delivery devices and the digital platform for asthma and chronic obstructive pulmonary disease (COPD). Aptar Pharma and Sonmol will work together on expanding Sonmol’s platform services to enable remote patient monitoring, improve patient and physician interactions, increase patient engagement and adherence, and improve health outcomes. The partnership will work with pharmaceutical and healthcare partners to accelerate the development, manufacturing, commercialization and supply of digital respiratory medicines, diagnostics and patient support services in China and other Asian markets for marketed and pipeline drugs.
The collaboration significantly bolster’s Aptar’s digital health offerings in Asia by combining Aptar Pharma’s expertise in connected drug delivery device development, innovation and quality manufacturing together with Sonmol’s connected devices, data platform and patient management services.
“We are pleased to partner with Sonmol to improve health outcomes by combining Aptar’s breadth of regulatory experience, quality focus and connected drug delivery device innovations with Sonmol’s patient adherence platform.” Xiangwei Gong, President of Aptar Asia, added, “We look forward to furthering digital respiratory medicines, diagnostics and patient support services in China and other Asian markets,” Stephan Tanda, Aptar President and CEO, said.